Preview

Нефрология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

ПОСТТРАНСПЛАНТАЦИОННЫЕ ЛИМФОПРОЛИФЕРАТИВНЫЕ ЗАБОЛЕВАНИЯ У ПАЦИЕНТОВ С ПОЧЕЧНЫМ АЛЛОТРАНСПЛАНТАТОМ

https://doi.org/10.24884/1561-6274-2018-22-6-77-83

Полный текст:

Аннотация

Посттрансплантационные лимфопролиферативные заболевания (ПТЛЗ) являются серьезным осложнением после трансплантации почки, негативно влияющим на выживаемость реципиентов и трансплантатов. Важным фактором патогенеза ранних ПТЛЗ является активная инфекция, вызванная вирусом Эпштейна–Барра (ЭБВ), при этом поздние ПТЛЗ нередко бывают ЭБВ-негативными. В диагностике ПТЛЗ важную роль играет использование современных визуализационных методов исследования (компьютерная томография, позитронно-эмиссионная томография), а также морфологическое исследование пораженных органов. В статье рассматриваются классификация ПТЛЗ, факторы риска их развития, особенности патогенеза, подходы к профилактике и лечению.

Об авторах

E. И. Прокопенко
Кафедра трансплантологии, нефрологии и искусственных органов факультета усовершенствования врачей, Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского.
Россия

129110, Россия, Москва, ул. Щепкина, д. 61/2.

Прокопенко Елена Ивановна, д-р мед. наук.

Тел.: (495)6845791.



Е. О. Щербакова
Кафедра трансплантологии, нефрологии и искусственных органов факультета усовершенствования врачей, Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского.
Россия

129110, Россия, Москва, ул. Щепкина, д. 61/2.

Щербакова Евгения Оттовна, канд. мед. наук.

Тел.: (495)6845791.



Список литературы

1. Ватазин АВ, Дутов ВВ, Зулькарнаев АБ и др. Инфекционные осложнения после трансплантации почки. Урология 2013; 3:107–111

2. Ватазин АВ, Зулькарнаев АБ, Дмитриева НГ и др. Роль системы HLA в отторжении почечного трансплантата. Альманах клинической медицины 2013; 29:79–83

3. Petrara MR, Giunco S, Serraino D et al. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesisdriven treatment. Cancer Lett 2015; 369(1):37–44. doi: 10.1016/j.canlet.2015.08.007

4. Starzl TE, Porter KA, Iwatsuki S et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1:583–587

5. Swerdlow SH. Pathology. In: Dharnidharka VR, Green M, Webber SA, eds. Post-transplant lymphoproliferative disorders. Berlin and Heidelberg, Germany: Springer-Verlag; 2010: 89–104

6. Dierickx D, Tousseyn Th, Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood 2015; 126:2274–2283. doi: 10.1182/blood-2015-05-615872

7. Fellner MD, Durand KA, Solernou V et al. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders. Rev Argent Microbiol 2016; 48(2):110–118. doi: 10.1016/j.ram.2016.02.006

8. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Posttransplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL et al, eds. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France, 2008:343–349

9. Krishnamurthy S, Hassan A, Frater JL et al. Pathologic and clinical features of Hodgkin lymphoma–like posttransplant lymphoproliferative disease. Int J Surg Pathol 2010; 18(4):278–285. doi: 10.1177/1066896909338597

10. Morscio J, Dierickx D, Nijs J et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 2014; 38(7):875–886. doi: 10.1097/PAS.0000000000000234

11. Tiede C, Maecker-Kolhoff B, Klein C et al. Risk factors and prognosis in T-cell posttransplantation lymphoproliferative diseases: reevaluation of 163 cases. Transplantation 2013; 95(3):479–488. doi: 10.1097/TP.0b013e3182762e07

12. Herreman A, Dierickx D, Morscio J et al. Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases. Leuk Lymphoma 2013; 54(10):2190–2199. doi: 10.3109/10428194.2013.775436

13. Romero S, Montoro J, Guinot M et al. Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leuk Lymphoma 2018 Jul 3:1–9. doi: 10.1080/10428194.2018.1474462

14. Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007; 131(8): 1209–1218. doi: 10.1043/1543-2165(2007)131[1209:TCSOPL]2.0.CO;2

15. Kobayashi M, Asano N, Fukushima M, Honda T. Three different histological subtypes of Epstein-Barr virus-negative posttransplant lymphoproliferative disorder in a patient withhepatitis C infection. Int J Hematol 2014; 100: 307–311. doi: 10.1007/s12185-014-1599-6

16. Khan G, Hashim MH. Global burden of deaths from Epstein-Barrvirus attributable malignancies 1990-2010. Infect Agent Cancer 2014; 9:38. doi: 10.1186/1750-9378-9-38

17. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011; 86(2):206–209. doi: 10.1002/ajh.21911

18. Engels EA, Pfeiffer RM, Fraumeni Jr JF et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306:1891–1901

19. Ibrahim HA, Naresh KN. Posttransplant lymphoproliferative disorders. Adv Hematol 2012; 2012:230173. doi: 10.1155/2012/230173

20. Smets F, Sokal EM. Prevention and treatment for Epstein-Barr virus infection and related cancers. Recent Results Cancer Res 2014;193:173–190. doi: 10.1007/978-3-642-38965-8_10

21. Aguayo-Hiraldo P, Arasaratnam R, Rouce RH. Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease. Bol Med Hosp Infant Mex 2016; 73(1):31–40. doi: 10.1016/j.bmhimx.2015.11.007

22. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56(1):155–167. doi: 10.1016/j.critrevonc.2005.03.015

23. United States Organ Transplantation. 2012 Annual Data Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 2000–2010. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. Am J Transplant 2014; 14(Suppl 1):8–183

24. Steiner R, Kridel R, Giostra E et al. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland. Swiss Med Wkly 2018 Mar 8; 148: w14596. doi: 10.4414/smw.2018.14596

25. Piselli P, Serraino D, Segoloni GP et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer 2013; 49(2):336–344. doi: 10.1016/j.ejca.2012.09.013

26. Gwon JG, Kim YH, Han DJ. Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000. Asian J Surg 2018 Oct 13. pii: S1015–9584(18)30481-0. doi: 10.1016/j.asjsur.2018.09.002. [Epub ahead of print]

27. Rahimzadeh N, Otukesh H, Hoseini R, Riahifard A. Pretransplant Epstein-Barr virus serostatus and incidence of posttransplant lymphoproliferative disorder in pediatric renal transplants. Exp Clin Transplant 2013; 4:299–302. doi: 10.6002/ect.2012.0204

28. Kalinova L, Indrakova J, Bachleda P. Post-transplant lymphoproliferative disorder. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153(4):251–257

29. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4(10):757–768. doi: 10.1038/nrc1452

30. Petrara MR, Freguja R, Gianesin K et al. Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Front Microbiol 2013; 4:311. doi: 10.3389/fmicb.2013.00311

31. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 2007; 7(2):96–101. doi: 10.1016/j.autrev.2007.02.012

32. Terrin L, Dal Col J, Rampazzo E et al. Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. J Virol 2008; 82(20):10175–10187. doi: 10.1128/JVI.00321-08

33. Giunco S, Celeghin A, Gianesin K et al. Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus. Cell Death Dis 2015; 6:e1774. doi: 10.1038/cddis.2015.145

34. Draborg AH, Duus K, Houen G. Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol 2012; 2012: 370516. doi: 10.1155/2012/370516

35. Hong GK, Kumar P, Wang L et al. Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol 2005; 79(22):13984–13992. doi: 10.1128/JVI.79.22.13984-13992.2005

36. Maksten EF, Vase MØ, Kampmann J et al. Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study. Transplant Int 2016; 29:483–493. doi:10.1111/tri.12744

37. Khedmat H, Ghamar-Chehreh M E, Amini M et al. Localization of post-transplant lymphoproliferative disorders to the stomach might be associated with favorable outcome: a systematic review. Saudi J Kidney Dis Transpl 2014; 25(2): 353–361

38. Lake W, Chang JE, Kennedy T et al. A case series of primary central nervous system post-transplant lymphoproliferative disorder: imaging and clinical characteristics. Neurosurgery 2013; 72(6):960–970. doi: 10.1227/NEU.0b013e31828cf619

39. Obanor SO, Gruttadauria M, Applebaum K et al. Posttransplant lymphoproliferative disorder presenting as testicular lymphoma in a kidney transplant recipient: a case report and review of the literature. Hindawi Case Reports in Nephrology 2018. Article ID 9787093, 6 p. doi: 10.1155/2018/9787093

40. Thibaud V, Rivalan J, Llamas F et al. Plasmacytoma-like post-kidney-transplant lymphoproliferative disorder confined to renal allograft and urinary tract: A case report. Nephrol Ther 2018 Oct 6. pii: S1769–7255(18)30563-7. doi: 10.1016/j.nephro.2018.07.404

41. Evens AM, Choquet S, Kroll-Desrosiers AR et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant 2013; 13(6):1512–1522. doi: 10.1111/ajt.12211

42. Camacho JC, Moreno CC, Harri PA et al. Posttransplantation lymphoproliferative disease: proposed imaging classification. Radiographics 2014; 34:2025–2038. doi: 10.1148/rg.347130130

43. Li J, Liu Y, Wang Zh et al. Multimodality imaging features, treatment, and prognosis of post-transplant lymphoproliferative disorder in renal allografts. Medicine 2018; 97:17. doi: 10.1097/MD.0000000000010531

44. Demir E, Karaoglan C, Yegen G et al. Extreme hypercalcemia in a kidney transplant recipient. CEN Case Rep 2018; 7(2): 229–233. doi: 10.1007/s13730-018-0334-1

45. Sharfuddin A. Imaging evaluation of kidney transplant recipients. Semin Nephrol. 2011; 31: 259–271. doi: 10.1016/j.semnephrol.2011.05.005

46. Vrachliotis TG, Vaswani KK, Davies EA et al. CT findings in posttransplantation lymphoproliferative disorder of renal transplants. AJR Am J Roentgenol 2000; 175: 183–188. doi: 10.2214/ajr.175.1.1750183

47. Ginat DT, Purakal A, Pytel P. Susceptibility-weighted imaging and diffusion-weighted imaging findings in central nervous system monomorphic B cell post-transplant lymphoproliferative disorder before and after treatment and comparison with primary B cell central nervous system lymphoma. J Neurooncol 2015; 125:297–305. doi: 10.1007/s11060-015-1903-1

48. Metser U, Lo G. FDG-PET/CT in abdominal posttransplant lymphoproliferative disease. Br J Radiol 2016; 89:20150844. doi: 10.1259/bjr.20150844

49. Kitajima K, Sasaki H, Koike J et al. Asymptomatic posttransplant lymphoproliferative disorder diagnosed at one year protocol renal allograft biopsy. Nephrology (Carlton) 2014; 19(Suppl 3):42–44. doi: 10.1111/nep.12246

50. San-Juan R, Manuel O, Hirsch HH et al. Current preventive strategies and management of Epstein–Barr virusrelated post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. Clin Microbiol Infect 2015; 21:604. e1–604.e9. doi: 10.1016/j.cmi.2015.02.002

51. Pickhardt PJ, Siegel MJ. Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology 1999; 213: 73–78

52. Gottschalk S, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disorders. Annu Rev Med 2005; 56:29–44. doi: 10.1146/annurev.med.56.082103.104727

53. Rabot N, Buchler M, Foucher Y et al. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality. Steunstichting ESOT 2014; 27:956–965

54. Ferreira H, Bustorff M, Santos J et al. Post-transplant lymphoproliferative disorder: a single-center experience. Transplant Proc 2015; 47(4):981–984. doi: 10.1016/j.transproceed.2015.03.017

55. Wowro SJ, Schmitt KRL, Tong G et al. Effects of mTOR and calcineurin inhibitors combined therapy in Epstein-Barr virus positive and negative Burkitt lymphoma cells. Immunopharmacol. 2016; 30:9–17. doi: 10.1016/j.intimp.2015.11.020

56. Nieto-Rios JF, Gómez de Los Ríos SM, Serna-Higuita LM et al. Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor. Colomb Med (Cali) 2016; 47(4):196–202

57. Gonz´alez-Barca E, Domingo-Domenech E, Capote FJ et al; GEL/TAMO (Grupo Espan˜ ol de Linfomas); GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear); GOTEL (Grupo Oncol´ogico para el Tratamiento y Estudio de los Linfomas). Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 2007; 92(11):1489–1494. doi: 10.3324/haematol.11360

58. Choquet S, Oertel S, LeBlond V et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007; 86(8):599–607. doi: 10.1007/s00277-007-0298-2

59. Trappe R, Oertel S, Leblond V et al; German PTLD Study Group; European PTLD Network. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell posttransplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13(2):196–206. doi: 10.1016/S1470-2045(11)70300-X

60. Gottschalk S, Rooney CM. Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol 2015; 391:427–454. doi: 10.1007/978-3-319-22834-1_15

61. Dierickx D, Tousseyn T, Sagaert X et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma 2013; 54(11):2433–2440. doi: 10.3109/10428194.2013.780655

62. Ready E, Chernushkin K, Partovi N et al. Posttransplant Lymphoproliferative Disorder in Adults Receiving Kidney Transplantation in British Columbia: A Retrospective Cohort Analysis. Can J Kidney Health Dis 2018; 5:2054358118760831. doi: 10.1177/2054358118760831

63. Гаврилина ОА, Троицкая ВВ, Звонков ЕЕ и др. Лимфопролиферативное EBV-позитивное заболевание с поражением центральной нервной системы, ассоциированное с иммуносупрессией после органной трансплантации: длительная ремиссия после химиотерапевтического лечения. Тер Архив 2017; 89(7):69–75


Для цитирования:


Прокопенко E.И., Щербакова Е.О. ПОСТТРАНСПЛАНТАЦИОННЫЕ ЛИМФОПРОЛИФЕРАТИВНЫЕ ЗАБОЛЕВАНИЯ У ПАЦИЕНТОВ С ПОЧЕЧНЫМ АЛЛОТРАНСПЛАНТАТОМ. Нефрология. 2018;22(6):77-83. https://doi.org/10.24884/1561-6274-2018-22-6-77-83

For citation:


Prokopenko E., Shcherbakova E. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN PATIENTS WITH KIDNEY ALLOGRAFT. Nephrology (Saint-Petersburg). 2018;22(6):77-83. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-6-77-83

Просмотров: 172


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)